Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Gregorc, V; Novello, S; Lazzari, C; Barni, S; Aieta, M; Mencoboni, M; Grossi, F; De Pas, T; de Marinis, F; Bearz, A; Floriani, I; Torri, V; Bulotta, A; Cattaneo, A; Grigorieva, J; Tsypin, M; Roder, J; Doglioni, C; Levra, Mg; Petrelli, F; Foti, S; Viganò M, ; Bachi, A; Roder, H